Nordic digital therapeutics company SidekickHealth entered a deal with Pfizer to launch a disease management platform in Europe.
Pfizer continues to be at the forefront of the transformation of medicine and with SidekickHealth, aims to empower patients to take control of their health and focus in inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn’s disease (CD) and also for patients with rheumatoid arthritis (RA), atopic dermatitis (AD) and psoriatic arthritis (PsA) across European countries with first market of entry to be Finland.
This can be one of the biggest deals for the Iceland Company. We, Mellalta Meets, would like to share the key insights.
About SideKick digital therapeutics platform
The solution offers patients a new tool to help them maintain healthy lifestyles, improve their disease management and quality of life, while providing assistance and resources to facilitate easier and faster communication between them and their healthcare professional.
Sidekick Digital Therapeutics Platform specifications
A rich user experience for patients, in which they are motivated to manage their nutrition, exercise, sleep, stress and adherence to drugs. Additionally, they will receive educational information about their illness and are connected to a community of healthcare professionals and other patients who can share relevant health experiences and skills.
Digital therapeutics platform focused Therapeutic areas
Conditions of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn’s disease (CD) and therefore for patients with rheumatoid arthritis (RA), atopic dermatitis (AD) and psoriatic arthritis (PsA) are the focus indications of Pfizer’s strategy.
Sidekick co-founder and chief executive officer Dr. Tryggvi Thorgeirsson said,
“We founded the company six years ago on a strong belief that digital health solutions could and would expand the reach and impact of traditional treatment of chronic disease. Over the past six years, we have seen the world taking significant steps towards such a future, and this collaboration is an exciting example of that on a large scale,” he added
Future strategic plans
Once digital therapeutics platform is launched in Finland, Pfizer has plans to expand in neighboring countries such as Sweden, Belgium, the Netherlands, Ireland, Switzerland and Austria in 2020 for ulcerative colitis (UC) and Rheumatoid Arthritis (RA) indications. Find out the case study here.